CSI Market
Sign In | Register

Igm Biosciences Inc (IGMS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access IGMS quarterly Cash Flow →
The table below presents a historical view of Igm Biosciences Inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2024)
12 Months 		(Dec 31 2023) (Dec 31 2022) (Dec 31 2021) (Dec 31 2020)
Operating Activities
Income-195.80
Depreciation & amortization9.11
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-2.68
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation38.27
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Amortization Of Operating Lease Right Of Use Assets-
Increase Decrease In Deferred Rent-
Interest Expense Related Party-
Purchase Net Discount Premium On Marketable Securities4.04
Non Cash Lease Expense5.30
Increase Decrease In Operating Lease Liability-3.37
Income taxes0.08
Losses/ -gains on Investments net0.00
Increase (Decrease) in Income Taxes Receivable0.00
Increase (Decrease) in Accounts Payable-0.31
Increase (Decrease) in Accrued Liabilities-2.35
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.48
Other Working Capital1.12
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-6.88
Discontinued operations0.00
Net Cash flow from Operating Activities-153.00
Investing Activities
Capital Expenditures-5.85
Sale of Capital Items0.04
Proceeds from Sale and Maturity of Available-for-sale Securities289.40
Payments to Acquire Available-for-sale Securities, Debt-219.43
Real Estate Investments0.00
Proceeds From Sales Of Investments-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities64.16
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.46
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-113.28
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations113.11
Restricted Cash And Cash Equivalents0.17
Debt Conversion Converted Instrument Amount-
Proceeds From Exercise Of Stock Options And Purchases Under Employee Stock Purchase Plan-
Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs-
Payment Of Deferred Offering Costs-0.07
Proceeds From Issuance Of Common Stock In Public Offering And Private Placement Net Of Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities2.39
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-158.81
Total Cash Flow-86.45
4 historic quarters locked

Sign in to unlock the full Igm Biosciences Inc cash flow history.

Sign In Create Free Account

About Igm Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-25-034597

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License